We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks 2nd on this list. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a relatively ...
BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
BridgeBio (BBIO) rose 6.6% after a court filing disclosed a settlement in a generic patent case over Pfizer's (PFE) Vyndamax ...
BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...
A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout ...
CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: ...
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on April 18, 2026, the ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
BridgeBio rose 2.9% after a court filing appeared to indicate a settlement in a generic patent case over Pfizer's Vyndamax ...
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results